Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Pancreatic Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 36Irinotecan 27Specimen Handling 23Biopsy 20Chemotherapy, Adjuvant 17Capecitabine 14Cetuximab 13Magnetic Resonance Spectroscopy 12Folfox protocol 12Bevacizumab 12Neoadjuvant Therapy 10sargramostim 6aldesleukin 6Melphalan 6Radiotherapy 5Floxuridine 5Cyclophosphamide 5dehydroftorafur 4X-Rays 4Nivolumab 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Celecoxib 4fludarabine 3durvalumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colorectal Neoplasms × Vancomycin × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡